Valneva Shares Plunge Despite Positive Vaccine Trial Data

Valneva's Lyme disease vaccine missed its primary endpoint statistically but showed ~75% efficacy. Pfizer remains committed to a 2026 regulatory filing despite the market sell-off.

A dramatic sell-off sent Valneva's stock tumbling more than 35% following the latest Phase 3 trial results for its Lyme disease vaccine candidate, VLA15, developed in partnership with Pfizer. In the biotech sector, such a steep decline often signals a fatal blow for a clinical program. However, the two companies are interpreting the data differently from the market, maintaining their commitment to seek regulatory approval in the second half of 2026.

Statistical Nuance Drives Market Reaction

The core of the investor panic lies in a specific statistical outcome. The vaccine demonstrated robust efficacy, reaching up to 75% in preventing Lyme disease, alongside a favorable safety profile. The primary study endpoint was formally missed due to an unexpectedly low number of Lyme disease cases occurring among trial participants, which pushed the initial pre-defined statistical analysis below its required threshold. Wall Street punished the stock for this technical miss.

Pfizer's continued support for the program is based on a secondary analysis of the same dataset. This subsequent review showed the vaccine's efficacy narrowly exceeded the target value, providing the foundation for the planned regulatory submission.

Analysts Adjust Targets Amid Underlying Support

Market researchers at First Berlin Equity Research acknowledged the setback but highlighted the strong clinical signal of over 70% efficacy in individuals aged five and above. They reiterated their "Buy" recommendation for Valneva shares, though they substantially reduced their price target from €6.60 to €4.80.

Operationally, Valneva maintains a solid financial foundation, despite a projected revenue dip. Management forecasts 2026 sales between €155 million and €170 million, down from €174.7 million in 2025. This anticipated decrease stems from the planned conclusion of a third-party contract business. The company's cash position, standing at approximately €110 million, is deemed sufficient to fund near-term operational requirements.

Commercial Potential Remains Substantial

Beyond the Lyme disease program, Valneva is advancing the commercialization of its approved chikungunya vaccine, IXCHIQ. New data from a Brazilian pilot campaign involving more than 12,000 vaccinated individuals was presented at the World Vaccine Congress in Washington in early April.

Nevertheless, the company's most significant value driver is the potential Lyme disease market. Nearly 700,000 cases are diagnosed annually across the United States and Europe alone. A successful vaccine approval would trigger milestone payments worth $143 million to Valneva, plus double-digit percentage royalties on future sales. The planned regulatory filing in late 2026 represents the next major catalyst. At that point, the U.S. Food and Drug Administration will make a final determination on whether the data supports bringing the first new Lyme disease vaccine to market in over two decades.